Clinical pharmacist implementation of a medication assessment tool for long-term management of atrial fibrillation in older persons

Keywords: Atrial Fibrillation, Disease Management, Drug Utilization Review, Medication Therapy Management, Inappropriate Prescribing, Pharmaceutical Services, Pharmacists, Aged, Clinical Audit, Malta

Abstract

Background: Optimisation of drug therapy is important in the older population and may be facilitated by medication assessment tools (MATs).

Objective: The purpose of the study was to evaluate whether appropriateness of drug therapy and clinical pharmacist intervention documentation improved following implementation of a previously developed MAT for the long-term management of atrial fibrillation (MAT-AF).

Methods: Adherence to MAT-AF review criteria and clinical pharmacist intervention documentation was assessed by the researcher pre-MAT implementation in 150 patients aged ≥60 years admitted to a rehabilitation hospital with a diagnosis of atrial fibrillation. MAT-AF was introduced as a clinical tool in the hospital for identification of pharmaceutical care issues in atrial fibrillation patients. Adherence to MAT-AF and pharmacist intervention documentation were assessed by the researcher post-MAT implementation for a further 150 patients with the same inclusion criteria. Logistic regression analysis and measurement of odds ratio was used to identify differences in adherence to MAT-AF pre- and post-MAT implementation. The differences between two population proportions z-test was used to compare pharmacist intervention documentation pre- and post-MAT implementation.

Results: Adherence to MAT-AF criteria increased from 70.9% pre-implementation to 89.6% post-implementation. MAT-AF implementation resulted in a significant improvement in prescription of anticoagulant therapy (OR 4.07, p<0.001) and monitoring of laboratory parameters for digoxin (OR 10.40, p<0.001). Clinical pharmacist intervention documentation improved significantly post-implementation of MAT-AF (z-score 20.249, p<0.001).

Conclusions: Implementation of MAT-AF within an interdisciplinary health care team significantly improved the appropriateness of drug therapy and pharmacist intervention documentation in older patients with atrial fibrillation. 

Downloads

Download data is not yet available.

References

Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care. Arch Intern Med. 2006;166(9):955-964. https://dx.doi.org/10.1001/archinte.166.9.955

Castelino RL, Bajorek BV, Chen TF. Targeting suboptimal prescribing in the elderly: A review of the impact of pharmacy services. Ann Pharmacother. 2009;43(6):1096-1106. https://dx.doi.org/10.1345/aph.1L700

Kaur S, Mitchell G, Vitetta L, Roberts MS. Interventions that can reduce inappropriate prescribing in the elderly. Drugs Aging. 2009;26(12):1013-1028. https://dx.doi.org/10.2165/11318890-000000000-00000

Spinewine A, Fialova D, Byrne S. The role of the pharmacist in optimizing pharmacotherapy in older people. Drugs Aging. 2012;29(6):495-510. https://dx.doi.org/10.2165/11631720-000000000-00000

Cooper JA, Cadogan CA, Patterson SM, Kerse N, Bradley MC, Ryan C, Hughes CM. Interventions to improve the appropriate use of polypharmacy in older people: A Cochrane systematic review. BMJ Open. 2015;5(12):e009235. https://dx.doi.org/10.1136/bmjopen-2015-009235

American Society of Health-System Pharmacists (ASHP). ASHP guidelines on documenting pharmaceutical care in patient medical records. Am J Health-Syst Pharm. 2003;60(7):705-707. https://dx.doi.org/10.1093/ajhp/60.7.705

Royal Pharmaceutical Society. Guidance on recording of interventions. Pharm J. 2006;276:517-518.

Page RL, Linnebur SA, Bryant LL, Ruscin JM. Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. Clin Interv Aging. 2010;5:75-87. https://dx.doi.org/10.2147/CIA.S9564

Gauci M, Wirth F, Camilleri L, Azzopardi LM, Serracino-Inglott A. Assessing appropriateness of drug therapy in older persons: Development and application of a medication assessment tool for long-term management of atrial fibrillation. Pharm Pract (Granada). 2017;15(4):1021-1025. https://dx.doi.org/10.18549/pharmpract.2017.04.1021

January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071-2104. https://dx.doi.org/10.1161/cir.0000000000000041

National Institute for Health and Care Excellence (NICE). Atrial fibrillation: The management of atrial fibrillation. Clinical guideline 180. UK: NICE; 2014.

Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, Healey JS, Bell A, Pilote L, Andrade JG, Mitchell LB, Atzema C, Gladstone D, Sharma M, Verma S, Connolly S, Dorian P, Parkash R, Talajic M, Nattel S, Verma A. 2016 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2016;30(10):1114-1130. https://dx.doi.org/10.1016/j.cjca.2016.07.591

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(38):2893-2962. https://dx.doi.org/10.1093/eurheartj/ehw210

Ziff OJ, Camm AJ. Individualized approaches to thromboprophylaxis in atrial fibrillation. Am Heart J. 2016;173:143-158. https://dx.doi.org/10.1016/j.ahj.2015.10.021

Electronic Medicines Compendium (eMC). Summary of product characteristics of digoxin 0.0625mg tablets. UK: eMC, January 2018. https://www.medicines.org.uk/emc/product/5464 (accessed Jul 5, 2018).

Electronic Medicines Compendium (eMC). Summary of product characteristics of amiodarone 200mg tablets. UK: eMC; May 2017. https://www.medicines.org.uk/emc/product/6018 (accessed Jul 5, 2018).

Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Wann LS, Camm AJ. Atrial fibrillation guidelines across the Atlantic: A comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J. 2013;34(20):1471-1474. https://dx.doi.org/10.1093/eurheartj/ehs446

Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, Sanders GD. Rate- and rhythm-control therapies in patients with atrial fibrillation: A systematic review. Ann Intern Med. 2014;160(11):760-773. https://dx.doi.org/10.7326/m13-1467

Mamo M, Wirth F, Azzopardi LM, Serracino-Inglott A. Standardising pharmacist patient-profiling activities in a rehabilitation hospital in Malta. Eur J Hosp Pharm. 2014;21(1):49-53. https://dx.doi.org/10.1136/ejhpharm-2013-000351

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-272. https://dx.doi.org/10.1378/chest.09-1584

Lefebre MD, St-Onge M, Glazer-Cavanagh M, Bell L, Nam Kha Nguyen J, Viet-Quoc Nguyen P, Tannenbaum C. The effect of bleeding risk and frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: The FRAIL-AF study. Can J Cardiol. 2016;32(2):169-176. https://dx.doi.org/10.1016/j.cjca.2015.05.012

Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest. 2010;138(5):93-100. https://dx.doi.org/10.1378/chest.10-0134

Suarez Fernandez CS, Formiga F, Camafort M, Cepeda Rodrigo JM, Diez-Manglano J, Pose Reino A, Tiberio G, Mostaza JM. Antithrombotic treatment in elderly patients with atrial fibrillation: A practical approach. BMC Cardiovascular Disorders. 2015;15:143. https://dx.doi.org/10.1186/s12872-015-0137-7

Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E. Warfarin vs. aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet. 2007;370(9586):493-503. https://dx.doi.org/10.1016/S0140-6736(07)61233-1

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. https://dx.doi.org/10.1016/S0140-6736(13)62343-0

Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157-164. https://dx.doi.org/10.1161/circulationaha.114.012061

Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: A systematic review. Age Ageing. 2011;40(6):675-683. https://dx.doi.org/10.1093/ageing/afr097

Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161(2):241-246. https://dx.doi.org/10.1016/j.ahj.2010.11.002

Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY. Prior history of falls and risk of outcomes in atrial fibrillation: The Loire Valley Atrial Fibrillation Project. Am J Med. 2014;127(10):972-978. https://dx.doi.org/10.1016/j.amjmed.2014.05.035

Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot JM, Boulanger E, Puisieux F, Chassagne P. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: Comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71-76. https://dx.doi.org/10.1111/jgs.13200

Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677-685. https://dx.doi.org/10.1001/archinte.159.7.677

Donze J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, Aujesky D. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125(8):773-778. https://dx.doi.org/10.1016/j.amjmed.2012.01.033

Published
2019-03-18
How to Cite
1.
Gauci M, Wirth F, Azzopardi LM, Serracino-Inglott A. Clinical pharmacist implementation of a medication assessment tool for long-term management of atrial fibrillation in older persons. Pharm Pract (Granada) [Internet]. 2019Mar.18 [cited 2019Jun.16];17(1):1349. Available from: https://www.pharmacypractice.org/journal/index.php/pp/article/view/1349
Section
Original Research